Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Boehringer Ingelheim
Chubb
McKesson
UBS
QuintilesIMS
Farmers Insurance
Healthtrust
Deloitte

Generated: June 23, 2018

DrugPatentWatch Database Preview

Peginesatide acetate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for peginesatide acetate and what is the scope of peginesatide acetate freedom to operate?

Peginesatide acetate
is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Peginesatide acetate has one hundred and twelve patent family members in thirty-two countries.

Summary for peginesatide acetate
International Patents:112
US Patents:6
Tradenames:2
Applicants:1
NDAs:1
Clinical Trials: 973
Formulation / Manufacturing:see details
DailyMed Link:peginesatide acetate at DailyMed

US Patents and Regulatory Information for peginesatide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for peginesatide acetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,855,175 Peptides that bind to the erythropoietin receptor ➤ Sign Up
8,729,030 Peptides that bind to the erythropoietin receptor ➤ Sign Up
7,906,485 Erythropoietin receptor peptide formulations and uses ➤ Sign Up
8,324,159 Erythropoietin receptor peptide formulations and uses ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
UBS
US Department of Justice
Federal Trade Commission
Cantor Fitzgerald
US Army
QuintilesIMS
Dow
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.